ELDN vs. IMMX, ANEB, TLSA, KZR, CALC, KRON, CKPT, CARM, EGRX, and AEON
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Immix Biopharma (IMMX), Anebulo Pharmaceuticals (ANEB), Tiziana Life Sciences (TLSA), Kezar Life Sciences (KZR), CalciMedica (CALC), Kronos Bio (KRON), Checkpoint Therapeutics (CKPT), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
Eledon Pharmaceuticals (NASDAQ:ELDN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Eledon Pharmaceuticals received 21 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 71.43% of users gave Eledon Pharmaceuticals an outperform vote.
Eledon Pharmaceuticals' return on equity of -43.52% beat Immix Biopharma's return on equity.
Eledon Pharmaceuticals currently has a consensus target price of $11.67, indicating a potential upside of 316.67%. Immix Biopharma has a consensus target price of $14.00, indicating a potential upside of 522.22%. Given Immix Biopharma's higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Eledon Pharmaceuticals.
In the previous week, Eledon Pharmaceuticals had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 15 mentions for Eledon Pharmaceuticals and 9 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.15 beat Eledon Pharmaceuticals' score of 0.73 indicating that Immix Biopharma is being referred to more favorably in the news media.
56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 19.4% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 55.9% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Eledon Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
Immix Biopharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Eledon Pharmaceuticals beats Immix Biopharma on 8 of the 14 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
